Home › Cancro al seno › Nevada
Studi clinici su Cancro al seno nello stato di Nevada
19 studi su Cancro al seno cercano partecipanti presso sedi nello stato di Nevada.
Città nello stato di Nevada
Testo ufficiale dello studio (inglese)
Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
- Cancer Care Specialists, Reno
In reclutamentoFase 3
Età da 18 a 100 · Tutti i sessi · Aggiornato il 2 ott 2026 · NCT05827081Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Carson Tahoe Regional Medical Center, Carson City
- Comprehensive Cancer Centers of Nevada - Henderson, Henderson
- Comprehensive Cancer Centers of Nevada-Horizon Ridge, Henderson
- e altri 25
In reclutamentoStudio osservazionaleVolontari sani benvenuti
Età da 40 a 75 · Tutti i sessi · Aggiornato il 2 ott 2026 · NCT05334069A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer
- Cancer Care Specialists, Reno
In reclutamentoFase 2
Età 18 e oltre · Tutti i sessi · Aggiornato il 1 ott 2026 · NCT06369285A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
- Optum Care Cancer Center ( Site 0050), Las Vegas
- Renown Regional Medical Center ( Site 0041), Reno
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 25 set 2026 · NCT06966700A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer
- Renown Regional Medical Center, Reno
In reclutamentoFase 1/2
Età 18 e oltre · Tutti i sessi · Aggiornato il 10 set 2026 · NCT03424005A Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast Cancer
- Research Site, Reno
In reclutamentoFase 3
Età da 18 a 130 · Tutti i sessi · Aggiornato il 8 set 2026 · NCT07647328Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
- Renown Health Medical Oncology, Reno
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 3 set 2026 · NCT06982521Evaluating Minimal Residual Disease (MRD) Through Longitudinal Circulating Tumor DNA (ctDNA) Profiling in Breast Malignancies
- Cancer Care Specialist of Reno, Reno
In reclutamentoStudio osservazionale
Età da 18 a 99 · Tutti i sessi · Aggiornato il 3 set 2026 · NCT07211178Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
- Carson Tahoe Regional Medical Center, Carson City
- Comprehensive Cancer Centers of Nevada - Henderson, Henderson
- Comprehensive Cancer Centers of Nevada-Horizon Ridge, Henderson
- e altri 25
In reclutamentoFase 3
Età da 18 a 60 · Donne · Aggiornato il 2 set 2026 · NCT05879926A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
- Comprehensive Cancer Centers of Nevada, Las Vegas
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 28 ago 2026 · NCT07029399A Pivotal Phase II Clinical Trial of Utidelone Injection Plus Capecitabine in HER2-negative Breast Cancer Patients With Brain Metastases
- Comprehensive Cancer Centers of Nevada, Las Vegas
In reclutamentoFase 2
Età 18 e oltre · Tutti i sessi · Aggiornato il 21 ago 2026 · NCT06764940Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects
- Comprehensive Cancer Centers of Nevada, Henderson
In reclutamentoFase 3
Età da 18 a 100 · Tutti i sessi · Aggiornato il 6 ago 2026 · NCT05232916A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
- Comprehensive Cancer Centers of Nevada, Las Vegas
In reclutamentoFase 1/2
Età 18 e oltre · Tutti i sessi · Aggiornato il 29 giu 2026 · NCT05377996Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
- Renown Regional Medical Centre, Reno
- Cancer Care Specialists, Reno
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 22 giu 2026 · NCT05696626A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
- Comprehensive Cancer Centers of Nevada, Henderson
- Comprehensive Cancer Centers of Nevada, Henderson
- Comprehensive Cancer Centers of Nevada, Las Vegas
- e altri 3
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 6 mag 2026 · NCT07062965De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
- OptumCare Cancer Care at Seven Hills, Henderson
- OptumCare Cancer Care at Charleston, Las Vegas
- Radiation Oncology Centers of Nevada Central, Las Vegas
- e altri 8
In reclutamentoFase 3
Età da 50 a 70 · Tutti i sessi · Aggiornato il 23 apr 2026 · NCT04852887A Study to Evaluate the Safety and Tolerability of TOS-358 in Women With HR+ HER2- Breast Cancer
- Comprehensive Cancer Centers of Nevada, Las Vegas
In reclutamentoFase 1
Età 18 e oltre · Donne · Aggiornato il 22 apr 2026 · NCT05683418Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
- OptumCare Cancer Care at Seven Hills, Henderson
- OptumCare Cancer Care at Charleston, Las Vegas
In reclutamentoStudio osservazionale
Età 18 e oltre · Tutti i sessi · Aggiornato il 17 mar 2026 · NCT06418204First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer
- Renown Regional Medical Center, Reno
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 22 set 2025 · NCT05216432Fonte: ClinicalTrials.gov, dati recuperati il 5 ott 2026. Ogni studio stabilisce i propri criteri di idoneità; è il team di ricerca a decidere chi può partecipare.